ClinicalTrials.gg
CompletedNCT03547908AllianceUpdated Mar 19, 2025Results posted

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

A Phase 3 interventional study of B/F/TAF and Placebo to match DTG in HIV-1/HBV Co-Infection, sponsored by Gilead Sciences. Completed at 69 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in treatment-naïve and HIV-1 and hepatitis B virus (HBV) adults.

02

Conditions studied

  • HIV-1/HBV Co-Infection

Browse trials for

03

In context

Coinfection

92 studies on the registry are indexed under Coinfection; 12 are open to participants now.

This study's enrollment of 244 is above the median of 75 across 50 interventional studies indexed under Coinfection.

Browse Coinfection studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • type 1 (HIV-1) co-infection:

    • Must be HIV antiretroviral treatment naive with plasma HIV-1 ribonucleic acid (RNA) ≥ 500 copies/mL at screening
    • ≤ 10 days of prior therapy with any antiretroviral agent, including lamivudine and entecavir, following a diagnosis of HIV-1 infection (except the use for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), up to one month prior to screening)
    • Screening genotype report must show sensitivity to emtricitabine (FTC) and tenofovir (TFV). This report will be provided by Gilead Sciences. Alternatively, if genotype results from a local laboratory obtained ≤ 90 days prior to screening visit date show sensitivity to these drugs, this genotype will be acceptable to fulfill this inclusion criterion in the event that the genotype obtained at screening is not yet available and all other inclusion/exclusion criteria have been confirmed
  • co-infection:

    • Must be hepatitis B virus (HBV) treatment naive (defined as \< 12 weeks of oral antiviral treatment)
    • Screening HBV deoxyribonucleic acid (DNA) ≥ 2000 IU/mL
  • Hepatic transaminases ( (AST) and alanine aminotransferase (ALT)) ≤ 10 x (ULN)
  • Total ≤ 2.5 x ULN

Key Exclusion Criteria:

  • virus (HCV) antibody positive and HCV RNA detectable
  • Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding) or with -Turcotte (CPT) C impairment
  • Current alcohol or substance use judged by the Investigator to potentially interfere with study compliance
  • Active, serious infections (other than HIV-1 and HBV infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1
  • Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    Blinded Phase: B/F/TAF

    Participants who are HIV-1 and HBV co-infected and treatment-naïve will receive Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination (FDC) tablet in addition to placebo to match (PTM) dolutegravir (DTG) tablet and PTM FDC emtricitabine/ tenofovir desoproxil fumarate (F/TDF) tablet for 96 weeks.

    Drug: B/F/TAF · Drug: Placebo to match DTG · Drug: Placebo to match F/TDF

  • Active comparator
    Blinded Phase: DTG+F/TDF

    Participants who are HIV-1 and HBV co-infected and treatment-naïve will receive DTG and FDC F/TDF in addition to PTM B/F/TAF for 96 weeks.

    Drug: DTG · Drug: F/TDF · Drug: Placebo to match B/F/TAF

  • Experimental
    Open-label Extension Phase: B/F/TAF from B/F/TAF

    After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 48 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.

    Drug: B/F/TAF

  • Experimental
    Open-label Extension Phase: B/F/TAF from DTG+F/TDF

    After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 48 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.

    Drug: B/F/TAF

Interventions

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food

    Also known as: Biktarvy®

  • DrugPlacebo to match DTG

    Tablet administered orally once daily, without regard to food

  • DrugPlacebo to match F/TDF

    Tablet administered orally once daily, without regard to food

  • DrugDTG

    50 mg tablet administered orally once daily, without regard to food

  • DrugF/TDF

    200/300 mg tablet administered orally once daily, without regard to food

    Also known as: Truvada®

  • DrugPlacebo to match B/F/TAF

    Tablet administered orally once daily, without regard to food

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint)

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded-off.

    Time frame: Week 48

  2. Percentage of Participants With Plasma Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 as Defined by Missing = Failure Approach (Co-primary Endpoint)

    This outcome measure was analyzed using a Missing = Failure approach. In this approach, all missing data were treated as HBV DNA ≥ 29 IU/mL. Percentages were rounded-off.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which was defined as a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded-off.

    Time frame: Week 96

  2. Change From Baseline in CD4 Cell Count at Week 48

    Time frame: Baseline, Week 48

  3. Change From Baseline in CD4 Cell Count at Week 96

    Time frame: Baseline, Week 96

  4. Change From Baseline in Percentage of CD4 Cells at Week 48

    Time frame: Baseline, Week 48

  5. Change From Baseline in Percentage of CD4 Cells at Week 96

    Time frame: Baseline, Week 96

  6. Percentage of Participants With Plasma HBV DNA < 29 IU/mL at Week 96

    This outcome measure was analyzed using a Missing = Failure approach. In this approach, all missing data were treated as HBV DNA ≥ 29 IU/mL. Percentages were rounded-off.

    Time frame: Week 96

  7. Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 by American Association for the Study of Liver Diseases (AASLD) Criteria

    ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given post baseline visit. The upper limit of the normal range (ULN) for ALT using the 2018 AASLD normal range was ≤ 25 U/L for females and ≤ 35 U/L for males. The Missing = Failure approach was used for this analysis. Percentages were rounded off.

    Time frame: Week 48

  8. Percentage of Participants With ALT Normalization at Week 96

    ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given post baseline visit. The upper limit of the normal range (ULN) for ALT using the 2018 AASLD normal range was ≤ 25 U/L for females and ≤ 35 U/L for males. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.

    Time frame: Week 96

  9. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48

    HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a post baseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative or missing at baseline to positive at a post baseline visit. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.

    Time frame: Week 48

  10. Percentage of Participants With HBsAg Loss at Week 96

    HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a post baseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative or missing at baseline to positive at a post baseline visit. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.

    Time frame: Week 96

07

Results

Posted Mar 15, 2023

Participant flow

Participants were enrolled at study sites in the North American, Asian, and European regions.

Blinded Phase
Participant flow — Blinded Phase
MilestoneBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFOpen-Label Extension Phase: B/F/TAF From B/F/TAFOpen-Label Extension Phase: B/F/TAF From DTG+F/TDF
Started12212200
Completed11111300
Not completed11900
Withdrew: Lost to follow-up3300
Withdrew: Withdrew consent2300
Withdrew: Investigator's discretion2100
Withdrew: Death2000
Withdrew: Non-compliance with study drug0200
Withdrew: Adverse event1000
Withdrew: Randomized but never treated1000
Open-label Extension Phase
Participant flow — Open-label Extension Phase
MilestoneBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFOpen-Label Extension Phase: B/F/TAF From B/F/TAFOpen-Label Extension Phase: B/F/TAF From DTG+F/TDF
Started009589
Completed009188
Not completed0041
Withdrew: Lost to follow-up0031
Withdrew: Death0010

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint)

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded-off.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint)
percentage of participantsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint)95.091.0
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Difference in percentages: 4.1 · 95.001% CI -2.5 to 10.8The difference in percentages of participants between groups and their 95.001% confidence intervals (CI)s were calculated based on Mantel-Haenszel (MH) proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL).
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Cochran-Mantel-Haenszel · p = 0.2113The p-value was calculated from Cochran-Mantel-Haenszel (CMH) test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL).
PrimaryPercentage of Participants With Plasma Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 as Defined by Missing = Failure Approach (Co-primary Endpoint)

This outcome measure was analyzed using a Missing = Failure approach. In this approach, all missing data were treated as HBV DNA ≥ 29 IU/mL. Percentages were rounded-off.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 as Defined by Missing = Failure Approach (Co-primary Endpoint)
percentage of participantsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Percentage of Participants With Plasma Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 as Defined by Missing = Failure Approach (Co-primary Endpoint)63.043.4
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Difference in percentages: 16.6 · 95.001% CI 5.9 to 27.3
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Cochran-Mantel-Haenszel · p = 0.0023The p-value was from CMH test stratified by baseline HBeAg status (positive vs negative) and HBV DNA category (\< 8 log10 IU/mL vs ≥ 8 log10 IU/mL).
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which was defined as a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Percentages were rounded-off.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm87.487.7
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Cochran-Mantel-Haenszel · p = 0.9427 (P-value for the superiority test comparing the percentages of participants with HIV-1 RNA \< 50 copies/mL between treatment groups was from the CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).) · Difference in percentages: -0.3 · 95% CI -8.9 to 8.3The difference in percentages of participants with HIV-1 RNA \< 50 copies/mL between treatment groups and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
SecondaryChange From Baseline in CD4 Cell Count at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4 Cell Count at Week 48
cells/µLBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Change From Baseline in CD4 Cell Count at Week 48200 ± 139.3175 ± 124.7
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · ANOVA · p = 0.1701 · Difference in least squares mean (lsm): 24 · 95% CI -10 to 58The difference in least squares means and its 95% CI were calculated using ANOVA model adjusted by the baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL).
SecondaryChange From Baseline in CD4 Cell Count at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · cells/uL
Change From Baseline in CD4 Cell Count at Week 96
cells/uLBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Change From Baseline in CD4 Cell Count at Week 96261 ± 161.6229 ± 174.0
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · ANOVA · p = 0.1853 (P-value was from ANOVA model adjusted by the baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in least squares means: 30 · 95% CI -14 to 74Difference in least squares means (Diff in LSM), and its 95% CI were from ANOVA model adjusted by the baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).
SecondaryChange From Baseline in Percentage of CD4 Cells at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percentage of CD4 cells
Change From Baseline in Percentage of CD4 Cells at Week 48
percentage of CD4 cellsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Change From Baseline in Percentage of CD4 Cells at Week 488.43 ± 4.17.75 ± 4.3
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · ANOVA · p = 0.2839 · Difference in least squares mean (lsm): 0.59 · 95% CI -0.49 to 1.67The difference in least squares means and its 95% CI were calculated using ANOVA model adjusted by the baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL).
SecondaryChange From Baseline in Percentage of CD4 Cells at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · percentage of CD4 cells
Change From Baseline in Percentage of CD4 Cells at Week 96
percentage of CD4 cellsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Change From Baseline in Percentage of CD4 Cells at Week 9610.69 ± 5.04710.42 ± 5.096
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · ANOVA · p = 0.8456 (P-value was from ANOVA model adjusted by the baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in lsm: 0.13 · 95% CI -1.20 to 1.46Difference in LSM and its 95% CI were from ANOVA model adjusted by the baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).
SecondaryPercentage of Participants With Plasma HBV DNA < 29 IU/mL at Week 96

This outcome measure was analyzed using a Missing = Failure approach. In this approach, all missing data were treated as HBV DNA ≥ 29 IU/mL. Percentages were rounded-off.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA < 29 IU/mL at Week 96
percentage of participantsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Percentage of Participants With Plasma HBV DNA < 29 IU/mL at Week 9674.870.5
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Cochran-Mantel-Haenszel · p = 0.6367 · Difference in percentages: 2.6 · 95% CI -8.3 to 13.4
SecondaryPercentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 by American Association for the Study of Liver Diseases (AASLD) Criteria

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given post baseline visit. The upper limit of the normal range (ULN) for ALT using the 2018 AASLD normal range was ≤ 25 U/L for females and ≤ 35 U/L for males. The Missing = Failure approach was used for this analysis. Percentages were rounded off.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 by American Association for the Study of Liver Diseases (AASLD) Criteria
percentage of participantsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 by American Association for the Study of Liver Diseases (AASLD) Criteria73.355.3
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Cochran-Mantel-Haenszel · p = 0.0655 · Difference in percentages: 17.1 · 95% CI -1.5 to 35.7The difference in percentages of participants between groups and their 95% CIs were calculated based on MH proportions adjusted by baseline HBeAg status (positive vs negative) and baseline HBV DNA (\< 8 log10 IU/mL vs ≥ 8 log10 IU/mL).
SecondaryPercentage of Participants With ALT Normalization at Week 96

ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given post baseline visit. The upper limit of the normal range (ULN) for ALT using the 2018 AASLD normal range was ≤ 25 U/L for females and ≤ 35 U/L for males. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With ALT Normalization at Week 96
percentage of participantsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Percentage of Participants With ALT Normalization at Week 9671.757.4
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Cochran-Mantel-Haenszel · p = 0.1253 · Difference in percentages: 14.1 · 95% CI -4.3 to 32.6Difference in the proportion between treatment groups and its 95% CI were calculated based on the MH proportions adjusted by baseline HBeAg status (positive vs negative) and baseline HBV DNA (\< 8 log10 IU/mL vs \>= 8 log10 IU/mL).
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48

HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a post baseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative or missing at baseline to positive at a post baseline visit. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
percentage of participantsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 4812.65.8
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Cochran-Mantel-Haenszel · p = 0.0591 · Difference in percentages: 7.1 · 95% CI -0.8 to 15.0Difference in the percentages between treatment groups and its 95% CI were calculated based on the MH proportions adjusted by baseline HBeAg status (positive vs negative) and baseline HBV DNA (\< 8 log10 IU/mL vs ≥ 8 log10 IU/mL).
SecondaryPercentage of Participants With HBsAg Loss at Week 96

HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a post baseline visit. HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative or missing at baseline to positive at a post baseline visit. The Missing = Failure approach was used for this analysis. Percentages were rounded-off.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 96
percentage of participantsBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDF
Percentage of Participants With HBsAg Loss at Week 9622.714.0
Statistical analysis
  • Blinded Phase: B/F/TAF vs Blinded Phase: DTG + F/TDF · Cochran-Mantel-Haenszel · p = 0.0655 (P value was from the CMH test stratified by baseline HBeAg status (positive vs negative) and baseline HBV DNA (\< 8 log10 IU/mL vs ≥ 8 log10 IU/mL). Statistically significant values are shown in bold.) · Difference in percentages: 9.3 · 95% CI -0.7 to 19.2Differences in percentages between treatment groups and their 95% CI were calculated based on MH proportions adjusted by baseline HBeAg status (positive vs negative) and baseline HBV DNA (\< 8 log10 IU/mL vs ≥ 8 log10 IU/mL).

Adverse events

Collected over Adverse Events: Up to the last dose date plus 30 days (maximum exposure: 5.1 years); All-Cause Mortality: Up to 5.3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinded Phase: B/F/TAF2/122 (1.6%)17/121 (14%)102/121 (84.3%)
Blinded Phase: DTG + F/TDF1/122 (0.8%)16/122 (13.1%)98/122 (80.3%)
Open-Label Extension Phase: B/F/TAF From B/F/TAF1/95 (1.1%)4/95 (4.2%)42/95 (44.2%)
Open-Label Extension Phase: B/F/TAF From DTG+F/TDF0/89 (0%)2/89 (2.2%)40/89 (44.9%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFOpen-Label Extension Phase: B/F/TAF From B/F/TAFOpen-Label Extension Phase: B/F/TAF From DTG+F/TDF
Covid-19Infections and infestations3/1216/1220/950/89
HaemorrhoidsGastrointestinal disorders0/1210/1222/950/89
Bacterial sepsisInfections and infestations0/1210/1220/951/89
Groin abscessInfections and infestations0/1210/1220/951/89
Pneumocystis jirovecii pneumoniaInfections and infestations0/1210/1220/951/89
Alcoholic seizureNervous system disorders0/1210/1220/951/89
Haemorrhoids thrombosedGastrointestinal disorders0/1210/1221/950/89
Anal abscessInfections and infestations1/1210/1221/950/89
Dermal cystSkin and subcutaneous tissue disorders0/1210/1221/950/89
Myocardial ischaemiaCardiac disorders1/1210/1220/950/89
Most frequent other events
Showing 10 of 25
Most frequent other events
EventBlinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFOpen-Label Extension Phase: B/F/TAF From B/F/TAFOpen-Label Extension Phase: B/F/TAF From DTG+F/TDF
Covid-19Infections and infestations48/12152/1225/954/89
Upper respiratory tract infectionInfections and infestations22/12120/1227/957/89
NasopharyngitisInfections and infestations18/12110/1227/955/89
PyrexiaGeneral disorders17/12116/1221/953/89
Alanine aminotransferase increasedInvestigations12/12115/1221/953/89
DiarrhoeaGastrointestinal disorders13/12111/1222/956/89
Weight increasedInvestigations13/12112/1226/956/89
HeadacheNervous system disorders13/1219/1221/950/89
SyphilisInfections and infestations8/12111/1222/951/89
RashSkin and subcutaneous tissue disorders10/1219/1222/950/89

Baseline characteristics

The Safely Analysis Set included participants who were randomized into the study and received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Blinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFTotal
<=18 years000
Between 18 and 65 years120121241
>=65 years112
Age, Continuous
Age, Continuous(years)Blinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFTotal
Mean33 ± 9.233 ± 9.433 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Blinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFTotal
Female9211
Male112120232
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Blinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFTotal
Hispanic or Latino71017
Not Hispanic or Latino114112226
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Blinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFTotal
Race — Asian108106214
Race — White10919
Race — Black268
Race — Other112
Region of Enrollment
Region of Enrollment(Participants)Blinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFTotal
Thailand553994
China272956
Malaysia152237
Taiwan5712
Dominican Republic4610
Turkey459
Japan257
Spain437
Hong Kong235
United States123
South Korea202
Puerto Rico011
CD4 Cell Count
CD4 Cell Count(cells/µL)Blinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFTotal
Mean282 ± 193.1266 ± 194.3274 ± 193.5
CD4 Percentage
CD4 Percentage(percentage of CD4 cells)Blinded Phase: B/F/TAFBlinded Phase: DTG + F/TDFTotal
Mean16.0 ± 8.6214.8 ± 8.2515.4 ± 8.44
08

Study locations

69 sites
  • Midway Immunology & Research
    Fort Pierce, Florida 34982, United States
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33401, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • The Crofoot Research Center, INC (DBA: Gordon E. Crofoot MD PA)
    Houston, Texas 77098, United States
  • Beijing Ditan Hospital Capital Medical University
    Beijing, 100015, China
  • Beijing YouAn Hospital, Capital Medical University
    Beijing, 100069, China
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, 100730, China
  • The First Hospital of Changsha
    Changsha, 410005, China
  • Chengdu Public Health Clinical Center
    Chengdu, 610066, China
  • Guangzhou Eighth people's Hospital
    Guangzhou, 510060, China
  • 1st Affiliated Hospital of Zhejiang University
    Hangzhou, China
  • The Second Hospital of Nanjing
    Nanjing, China
  • Shanghai Public Health Clinical Center
    Shanghai, 201058, China
  • Third People's Hospital Of Shenzhen
    Shenzhen, 518040, China
  • Instituto Dominicano de Estudios Virologicos (IDEV)
    Santo Domingo, 10103, Dominican Republic
  • Hôpital de la Croix Rousse
    Lyon, 69004, France
  • Evaggelismos General Hospital of Athens
    Athens, 10676, Greece
  • Korgialenio-Benakio Greek Red Cross General Hospital
    Athens, 11526, Greece
  • Laiko General Hospital
    Athens, 11527, Greece
  • AHEPA University Hospital of Thessaloniki
    Thessaloniki, 546 36, Greece
  • Prince of Wales Hospital
    Hong Kong, Hong Kong
  • Queen Elizabeth Hospital (QEH)
    Hong Kong, Hong Kong
  • Princess Margaret Hospital
    Kowloon, Hong Kong
  • National Hospital Organization Nagoya Medical Center
    Aichi, 460-0001, Japan
  • University of the Ryukyus Hospital
    Okinawa, 903-0215, Japan
  • Osaka City General Hospital
    Osaka, 534-0021, Japan
  • National Hospital Organization Osaka National Hospital
    Osaka, 540-0006, Japan
  • The Jikei University Hospital
    Tokyo, 105-8471, Japan
  • Juntendo University Hospital
    Tokyo, 113-8431, Japan
  • Center Hospital of the National Center for Global Health and Medicine
    Tokyo, 162-8655, Japan
  • Yokohama City University Hospital
    Yokohama, 236-0004, Japan
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Hospital Raja Permaisuri Bainun
    Ipoh, 31350, Malaysia
  • Hospital Raja Perempuan Zainab II
    Kota Bahru, 15580, Malaysia
  • Queen Elizabeth Hospital
    Kota Kinabalu, 88200, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 50603, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 53000, Malaysia
  • Hospital Sultanah Nur Zahirah
    Kuala Terengganu, 20400, Malaysia
  • Sarawak General Hospital
    Kuching, 93586, Malaysia
  • Hospital Pulau Pinang
    Pulau Pinang, 10450, Malaysia
  • Sungai Buloh Hospital
    Sungai Buloh, 47000, Malaysia
  • Hope Clinical Research
    San Juan, 00909, Puerto Rico
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital General Universitario Santa Lucia
    Cartagena, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital de Canarias
    Santa Cruz de Tenerife, 38320, Spain
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • CHUVI - Hospital Universitario Alvaro Cunqueiro
    Vigo, 36312, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 80756, Taiwan
  • Kaohsiung Veterans General Hospital
    Kaohsiung, 81362, Taiwan
  • Far Eastern Memorial Hospital
    New Taipei City, 22060, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
  • Taipei Veterans General Hospital
    Taipei City, 11217, Taiwan
  • National Taiwan University Hospital
    Taipei, 10048, Taiwan
  • Taipei City Hospital Linsen, Chinese Medicine and Kunming Branch
    Taipei, 10844, Taiwan
  • Ministry of Health and Welfare Taoyuan General Hospital
    Taoyuan City, 33004, Taiwan
  • Thai Red Cross AIDS Research Centre (HIV-NAT)
    Bangkok, 10330, Thailand
  • Faculty of Medicine Ramathibodi Hospital, Mahidol University
    Bangkok, 10400, Thailand
  • Siriraj Hospital
    Bangkok, 10700, Thailand
  • Faculty of Medicine, Chiang Mai University
    Chiang Mai, 50200, Thailand
  • Chiang Rai Reginal Hospital
    Chiang Rai, 57000, Thailand
  • Srinagarind Hospital
    Khon Kaen, 40002, Thailand
  • Bamrasnaradura Infectious Diseases Institute
    Nonthaburi, 11000, Thailand
  • Istanbul University Cerrahpasa Medical Faculty
    Istanbul, 34098, Turkey
  • Marmara University Pendik Training and Research Hospital
    Istanbul, 81190, Turkey
09

References and documents

Publications

  • Avihingsanon, A. 2022. Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir Disoproxil Fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE). AIDS, 29 July 29-2 August 2022, Montréal, Québec, Canada.
  • Avihingsanon A, Lu H, Leong CL, Hung CC, Koenig E, Kiertiburanakul S, Lee MP, Supparatpinyo K, Zhang F, Rahman S, D'Antoni ML, Wang H, Hindman JT, Martin H, Baeten JM, Li T; ALLIANCE Study Team. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. Lancet HIV. 2023 Oct;10(10):e640-e652. doi: 10.1016/S2352-3018(23)00151-0. Epub 2023 Jul 23. PubMed 37494942 ↗
  • Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data: Erratum. J Acquir Immune Defic Syndr. 2024 Oct 1;97(2):202. doi: 10.1097/QAI.0000000000003494. No abstract available. PubMed 39250654 ↗
  • Avihingsanon A, Lu H, Leong CL, Hung C-C, Kiertiburanakul S, Lee M-P, Supparatpinyo K, Zhang F, Hindman JT, Wang H, Liu H and Li T. Factors Associated with HBV Response to B/F/TAF vs. DTG + F/TDF at W96 in People with HIV-1 and HBV. CROI, March 3-6, 2024.
  • Avihingsanon A, Lu H, Leong C, Hung C, Koenig E, Kiertiburanakul S, et al. Week-96 results of ALLIANCE, a Phase 3, randomized, double-blind study comparing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in treatment-naive people with both HIV-1 and hepatitis B. 12th International AIDS Society Conference on HIV Science 2023, 23-26 July.
  • D'Antoni M, Andreatta K, Cox S, Chang S, Hindman J, Martin H, et al. HIV-1 resistance analysis of treatment-naive participants with HIV-1 and hepatitis B coinfection receiving bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir + emtricitabine/tenofovir disoproxil fumarate. European Meeting on HIV and Hepatitis 2023, 7-9 June, Rome, Italy.
  • Avihingsanon A, Leong C, Hung C, Koenig E, Lee M, Supparatpinyo K, et al. Predictors of hepatitis B treatment response in people with HIV-1/HBV coinfection. Conference on Retroviruses and Opportunistic Infections (CROI) 2023, 19-22 February; Seattle, Washington.
  • Avihingsanon A, Lu H, Leong C, Hung C, Koenig E, Kiertiburanakul S, et al. Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) as initial treatment in HIV/HBV coinfected adults (ALLIANCE). AIDS (Conference) 2022, 29 July 2 August; Montréal, Québec, Canada.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Feb 2022, 44 months.

Results were first posted in Mar 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2018
First posted
Jun 6, 2018
StartActual
May 30, 2018
Primary completionActual
Feb 25, 2022
CompletionActual
Mar 7, 2024
Results first posted
Mar 15, 2023
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03547908
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 6, 2018
Start date
May 30, 2018
Primary completion
Feb 25, 2022
Completion
Mar 7, 2024
Results posted
Mar 15, 2023
Last update
Mar 19, 2025

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion